Latest News - Movement Disorders

Monday, April 09, 2018

Topline Results From Phase 2a Study for Cannibinoid for Treating Tourette Syndrome

Therapix Biosciences (Tel Aviv, Israel) has announced results from its investigator-initiated phase 2a study at Yale University led by Michael Bloch and James Leckman to test Therapix’s compound…

Read the full story

Tuesday, April 03, 2018

New Wearable Tracker With Objective Measurements Improves Quality of Life and Clinical Outcomes for 43% of Patients with Parkinson’s Disease

Using the Personal Kinetigraph (PKG) smart watch (Global Kinetics Corporation, Ltd; Portsmouth, NH), which is a Food and Drug Administration (FDA)-cleared technology, researchers Parisa Farzanehfar, H…

Read the full story

Monday, March 12, 2018

Phase 1 Trial Initiated for Product Candidate CAD-1883, Hoped to Provide Treatment for Spinocerebellar Ataxia and Essential Tremor

Novel therapeutics developer, Cadent Therapeutics (Cambridge, Massachusetts) has initiated a phase 1 clinical trial for product candidate CAD-1883, which is an allosteric modulator of the small conduc…

Read the full story

Thursday, March 01, 2018

Biosimilar Being Developed for Botox

In a transatlantic collaboration, Mylan N.V. (Pittsburgh, Pennsylvania) and Revance Therapeutics, Inc. (Hertsfordshire, England) have reached an agreement to collaborate on the development and commerc…

Read the full story

Tuesday, February 27, 2018

Kenneth Marek, MD Joins the Michael J. Fox Foundation for Parkinson's Research as Scientific Advisor

The Michael J. Fox Foundation for Parkinson's Research (MJFF) announced that Kenneth Marek, MD, has joined the Foundation as Scientific Advisor. In this role, Dr. Marek will provide more dire…

Read the full story

Thursday, February 22, 2018

Tears May Contain a Biomarker for Parkinson's Disease

A preliminary study will be presented at the American Academy of Neurology (AAN) meeting in Los Angeles, April 21-27, that shows there may be a biomarker in tears for Parkinson’s disease (PD). …

Read the full story

Tuesday, February 20, 2018

Food and Drug Administration Approves Extended-Release Amantadine for Treatment of Parkinson's Disease and Drug-Induced Extrapyramidal Reactions in Adults

The Food and Drug Administration (FDA) approved Osmolex ER (Osmotica Pharmaceuticals; Bridgewater, NJ) an extended-release formulation of amantadine for the treatment of Parkinson’s disease (PD)…

Read the full story

Wednesday, February 14, 2018

Neurocrine Biosciences Receives Guidance from Food and Drug Administration for New Drug Application for Opicapone as Adjunct Therapy to Levodopa in Parkinson's Disease

Opicapone, a novel, once-daily, peripherally-acting, highly-selective catechol-o-methyltransferase (COMT) inhibitor that prolongs the effect of levodopa by decreasing the rate of conversion to 3-O-met…

Read the full story

Monday, February 12, 2018

Alkahest Receives Grant From the The Michael J. Fox Foundation for Parkinson's Research for Clinical Trial of GRF6019

On February 12, 2018, Alkahest, a privately-held clinical-stage company developing treatments for age-related diseases announced that they had received funding from the Michal J. Fox Foundation for Pa…

Read the full story

Friday, February 09, 2018

National Institutes of Health Researchers Adapt Test for Early Diagnosis of Parkinson's Disease and Dementia with Lewy Bodies

Acta Neuropathologica Communications published a paper by researchers at the National Institutes of Health (NIH) (Groveman BR, Orrù CD, and Hughson AG, et al. Acta Neuropathol Comm. 2018;6:publ…

Read the full story

Thursday, February 08, 2018

Two Surveys for Diagnosing Mild Cognitive Impairment in Parkinson's Disease

Approximately one-third of patients with Parkinson’s disease (PD) have dementia, leading to severe quality-of-life impairments in addition to those that are caused by the motor symptoms of PD. I…

Read the full story

Wednesday, February 07, 2018

Phase 3 Trial of P2B001 for Early-Stage Parkinson's Disease Begins With First Patients Receiving First Dose

The drug P2B001(Pharma Two B) is a combination product of pramipexole 0.6mg and rasagiline 0.75 mg given together once daily. Rasagiline is a monoamine oxidase inhibitor used to treat Parkinson&r…

Read the full story

Monday, February 05, 2018

Frozen Gait in Parkinson's Disease Is Influenced by Emotional Stimuli

In a study published in Movement Disorders, Lagravinese and colleagues have shown that gait initiation in patients with Parkinson’s disease (PD) is affected by the presence of an emotional stimu…

Read the full story

Tuesday, January 16, 2018

The Generational Technology Gap May Be Closing—Even in Patients with Dementia

Senior Helpers, a provider of in-home services for seniors who wish to remain in their homes despite age-related illnesses and mobility challenges including dementia, Alzheimer’s disease, and Pa…

Read the full story

Wednesday, January 10, 2018

Parkinson’s Outcomes Project Enrolls 10,000th Patient and Releases Key Findings

The "Parkinson's Outcomes Project," launched in 2009 as a small pilot and funded by the Parkinson's Foundation, met a major milestone goal with the enrollment of its 10,000th pa…

Read the full story
Load More